This deal was successfully consummated on June 10, 2020
Receive instant FREE access to constantly updated STML news related to the current takeover deal. Simply register by entering your email address to receive weekly publication updates. For more proprietary Merger Arbitrage Limited content and analysis on this buyout, click Stemline Therapeutics (STML). Proprietary commentary can also be accessed by simply entering a ticker symbol into the search box such as “STML“, or clicking on a stock ticker in the tag cloud at the foot of this article.
Traders and shareholders can review similar deal information on current merger stocks by first selecting “DEALS” from the main menu, then “Current Cash Deals” or “Current Stock Deals”. For previous acquisitions, select either “Closed Deals” or “Failed Deals“. Broader mergers and acquisitions news on other constituents of the T20 portfolio, please see our Spread Tracker News feed.
Stemline Therapeutics (NASDAQ: STML) Acquisition - Merger News and Events
The major Menarini Group and Stemline Therapeutics (STML) acquisition news updates & events are listed below. A comprehensive data source for traders & investors looking to familiarize themselves with the Menarini Group merger with Stemline Therapeutics (STML) and trade the merger arbitrage spread, or for existing shareholders wishing to stay abreast of the latest deal developments. Following the acquisition news and events section, there is an in-depth company profile.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and Europe. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies.
In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is headquartered in New York, New York.
